| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
NewcelX Ltd.$4.13
-0.1 (-2.36%)
D 31Pipeline Score Overvalued Biotech · Clinical
Market Cap
16.89 M
EPS
-
P/E Ratio
-
Value Trade
31.36 K
-6.23 %
Week
-8.93 %
1 Month
14.91 %
3 Month
-3.36 %
6 Month
-100 %
5 Year
-100 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
131.41 K
52 Week Range
1.83 - 307.99
% held by Insiders
53.01 %
% held by Institutions
0.02 %
Enterprise Value
15.05 M
Total Shares
5.34 M
Short %
2.48 %
Float Shares
2.42 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for NewcelX Ltd.
283Total events
3Upcoming
74Tier-1 (high impact)
2021 – 2026Coverage
Upcoming catalysts 3
Event history 280
Jul 8, 2026
▲Type B MeetingNCEL-101FDA Meeting
Successful FDA Type B Pre-IND meeting for NCEL-101
type 1 diabetessource ↗
Jul 1, 2026
▲Pre IND MeetingNCEL-101FDA Meeting
Successful FDA Pre-IND meeting for NCEL-101
type 1 diabetessource ↗
Jul 2026
◆Trial CompletionTrial
Preclinical study expected to be completed within 12-18 months
fentanyl dependencesource ↗
Jun 15, 2026
▲PublicationAstroRxPresentation
Successful completion of Phase 1/2a clinical trial in ALS (mentioned in publication context)
amyotrophic lateral sclerosissource ↗
Jun 2026
◆Pre IND MeetingNCEL-101FDA Meeting
Type B pre-IND meeting scheduled with FDA for NCEL-101
type 1 diabetessource ↗
May 27, 2026
●IND SubmissionNCEL-101IND
Pre-IND briefing package submitted to FDA for NCEL-101
type 1 diabetessource ↗
Apr 30, 2026
Apr 30, 2026
Apr 20, 2026
▲Partnership / LicenseNCEL-101Corporate
Strategic collaboration with Eledon Pharmaceuticals for tegoprubart
Type 1 Diabetessource ↗
Apr 20, 2026
◆Oral PresentationNCEL-101Presentation
Presentation at Swiss Biotech Conference
Type 1 Diabetessource ↗
Apr 1, 2026
▼Equity OfferingCorporate
Pricing of $1.35 million equity financing at $2.75 per share (30% premium)
Mar 9, 2026
▲Partnership / LicenseNCEL-101Corporate
Strategic collaboration with Eledon Pharmaceuticals to combine NCEL-101 with tegoprubart
Type 1 Diabetessource ↗
Drug Pipeline Intelligence
D31
Pipeline Score $8M
Pipeline ValueOvervalued
Valuation Signal3
Drugs Scored0.5x
rNPV / MCap Top 36%
Micro Cap (rank 581 of 906)
Percentile RankNewcelX Ltd. faces pipeline headwinds (31/100), with $618M risk-adjusted pipeline value, led by NLS-2 in Narcolepsy Type 1 (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NLS-2 Small molecule | Narcolepsy Type 1 | Phase 3 | NCT05914194 | 50% | $358M | NOT YET_RECRUITING | 48 | STALLED | C (48) | Jul 30, 2025 | - | LOW May 24, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
AstroRx® | multiple sclerosis | Phase 1/2a | 2026-06-15 | enhance myelin debris clearance by microglia; support lymphocyte-mediated immune regulation; accelerate oligodendrocyte progenitor cell (OPC) differentiation into oligodendrocytes Read More | NewcelX Publishes Peer-Reviewed Study Demonstrating Broad Therapeutic Potential of its Stem Cell Technology Platform Read More | |
AstroRx® | multiple sclerosis | Phase 1/2a | 2026-06-15 | enhance myelin debris clearance by microglia; support lymphocyte-mediated immune regulation; accelerate oligodendrocyte progenitor cell (OPC) differentiation into oligodendrocytes Read More | NewcelX Publishes Peer-Reviewed Study Demonstrating Broad Therapeutic Potential of its Stem Cell Technology Platform Read More | |
AstroRx® | multiple sclerosis | Phase 1/2a | 2026-06-15 | enhance myelin debris clearance by microglia; support lymphocyte-mediated immune regulation; accelerate oligodendrocyte progenitor cell (OPC) differentiation into oligodendrocytes Read More | NewcelX Publishes Peer-Reviewed Study Demonstrating Broad Therapeutic Potential of its Stem Cell Technology Platform Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in NCEL
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
NCEL Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
NCEL▲ +5.5%on this news
NewcelX Appoints World-Renowned Diabetes Cure-Focused Pioneer, Dr. Camillo Ricordi, to Scientific Advisory Board
NewcelX has appointed Dr. Camillo Ricordi to its Scientific Advisory Board, enhancing its focus on developing regenerative therapies for type 1 diabetes. This appointment follows a successful FDA Type B Pre-IND meeting for their lead program, NCEL-101, which outlines a clear regulatory path for upcoming clinical trials. Dr. Ricordi's extensive experience in diabetes research is expected to significantly support NewcelX's strategic initiatives.
Read more →NCELNewcelX Announces Successful FDA Pre-IND Meeting with Clear Path Forward for NCEL-101 Toward Starting Clinical Trials for Type 1 Diabetes
NewcelX Ltd. announced a successful Type B Pre-IND meeting with the FDA, receiving positive feedback on its development strategy for NCEL-101, a treatment for type 1 diabetes. The FDA's guidance allows NewcelX to advance toward clinical trials in combination with Eledon Pharmaceuticals' tegoprubart. This milestone is seen as a significant step toward developing a potentially transformative therapy for patients.
Read more →NCELNewcelX Publishes Peer-Reviewed Study Demonstrating Broad Therapeutic Potential of its Stem Cell Technology Platform
NewcelX has published a peer-reviewed study in Stem Cell Reports highlighting the potential of its AstroRx® therapy for treating chronic demyelinating diseases, including multiple sclerosis. The study demonstrates AstroRx®'s ability to enhance myelin debris clearance and promote oligodendrocyte differentiation. This publication supports NewcelX's ongoing development of scalable stem cell therapies and its lead candidate for type 1 diabetes.
Read more →NCEL▼ -7%on this news
To the shareholders of NewcelX AG, Kloten, Switzerland Zurich, June 5, 2026 Invitation to the Ordinary Shareholders' Meeting of NewcelX AG, Kloten, Switzerland Dear Shareholder, The board of directors of NewcelX A
NewcelX AG has invited shareholders to its ordinary shareholders' meeting scheduled for June 30, 2026. Key agenda items include the re-election of board members, approval of statutory financial statements for 2025, and examination of the compensation report. The company reported an operating loss for the year 2025, with an accumulated loss amounting to CHF 90,869,091. The board proposes to carry forward this loss to the next financial year, emphasizing the importance of stable governance amidst financial challenges.
Read more →NCEL▲ +9.5%on this news
NewCelX Ltd. Submits Pre-IND Package to the FDA for NCEL-101 for the Treatment of Type 1 Diabetes
NewCelX Ltd. has submitted a Pre-IND package to the FDA for NCEL-101, aiming to advance to a First-In-Human clinical trial for type 1 diabetes treatment. The therapy combines NCEL-101 with Eledon's tegoprubart, which has shown promise in preserving islet function in prior studies. A Type B pre-IND meeting is scheduled with the FDA to discuss further development plans.
Read more →NCEL▲ +28.9%on this news
NewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026
NewcelX reported its financial results for 2025 and highlighted its collaboration with Eledon Pharmaceuticals on NCEL-101, a potential treatment for Type 1 Diabetes. The company closed a financing round of approximately $3.4 million and appointed a new Chief Medical Officer to enhance its scientific leadership. Looking ahead, NewcelX anticipates accelerated development in 2026, despite facing financial losses and regulatory uncertainties.
Read more →NCEL▲ +6.4%on this news· ran to +85% by day 3
NewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech Conference
NewcelX Ltd. has updated its corporate presentation to emphasize its collaboration with Eledon Pharmaceuticals and the advancement of its Type 1 Diabetes program, NCEL-101. This partnership aims to integrate stem-cell-derived therapies with immune-modulation strategies to improve transplant outcomes. The company plans to showcase this strategy at the upcoming Swiss Biotech Conference.
Read more →NCEL▲ +10.8%on this news
NewcelX Announces Pricing of $1.35 Million Equity Financing at 30% Premium Pricing Financing reflects strong investor confidence and supports advancement of lead Type 1 Diabetes program
NewcelX Ltd. has announced the pricing of a $1.35 million equity financing at a 30% premium over the last closing price. This funding will support the advancement of its lead program, NCEL-101, aimed at treating Type 1 Diabetes. The financing reflects strong confidence from investors and includes participation from existing shareholders. The expected closing date for the offering is around April 15, 2026, conditional on customary closing conditions being met.
Read more →NCELNewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals (Nasdaq: ELDN) to Advance NCEL-101 Program for Type 1 Diabetes Collaboration Integrates Stem-Cell-Derived Islets with Targeted Immune Modulation
NewcelX has entered a strategic collaboration with Eledon Pharmaceuticals to enhance its NCEL-101 program for Type 1 Diabetes. This partnership aims to integrate NewcelX's stem-cell-derived therapies with Eledon's investigational anti-CD40L monoclonal antibody, facilitating improved immune modulation. The collaboration is expected to support better durability of cell grafts and streamline regulatory processes. Both companies anticipate that this initiative will help address critical unmet medical needs in diabetes treatment and advance clinical programs more efficiently.
Read more →NCELNewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes NewcelX Ltd. ("NewcelX") (Nasdaq: NCEL), a clinical-stage company advancing stem-cell-derived therapies for Type 1 Diabetes, today announced a...
NewcelX has announced a strategic collaboration with Eledon Pharmaceuticals to advance its NCEL-101 program aimed at treating Type 1 Diabetes. This partnership will integrate stem-cell-derived islets with Eledon's investigational anti-CD40L monoclonal antibody, tegoprubart, to enhance graft survival. The collaboration is expected to streamline development and establish a clearer regulatory pathway for NCEL-101.
Read more →NCELNewcelX Reports Peer-Reviewed Publication Supporting Mazindol IR/SR and Advances CVR Monetization Strategy Publication strengthens scientific positioning as Company progresses strategic discussions related to CVR-linked
NewcelX Ltd. announced a peer-reviewed publication that validates the clinical profile of Mazindol Immediate-Release/Sustained-Release (IR/SR), strengthening its strategic positioning in licensing and acquisition discussions. The article, published in a reputable journal, enhances buyer confidence and supports NewcelX's ongoing negotiations to maximize the asset's value under the Contingent Value Rights (CVR) framework. The company is currently engaged in advanced talks with multiple parties interested in licensing or acquiring Mazindol ER, aiming to convert its scientific strengths into successful financial outcomes. This significant milestone reflects over 20 years of research and development dedicated to the drug's potential applications in various CNS disorders.
Read more →NCELNewcelX Reports Peer-Reviewed Publication Supporting Mazindol IR/SR and Advances CVR Monetization Strategy NewcelX Ltd. ("NewcelX" or the "Company") (Nasdaq: NCEL), a clinical-stage biopharmaceutical company advancing stem-cell-derived therapies for Type 1 ...
NewcelX Ltd. announced a peer-reviewed publication validating Mazindol ER's clinical profile, enhancing its strategic positioning for potential licensing and acquisition discussions. The publication, featured in Clinical Drug Investigation, supports the company's efforts to maximize the value of its Contingent Value Right (CVR) linked to Mazindol ER. This milestone is expected to accelerate negotiations and improve buyer confidence.
Read more →NCELNewcelX Announces Updated Corporate Presentation Ahead of Key Spring 2026 Investor and Partnering Conferences Reinforces strategic focus on Type 1 Diabetes cell therapy and highlights expansion of Scientific Advisory Boa
NewcelX Ltd. (NASDAQ: NCEL) has announced an updated corporate presentation ahead of major spring 2026 investor and partnering conferences. The presentation emphasizes the company's strategic commitment to developing cell therapies for Type 1 Diabetes, showcasing recent scientific advancements and clinical objectives. It also highlights the expansion of the Scientific Advisory Board and leadership team, aiming to strengthen its capabilities in cell therapy development. NewcelX plans to engage with potential partners and investors during the upcoming conferences and is eager to share its progress within the biotechnology community.
Read more →NCELNewcelX Announces Updated Corporate Presentation Ahead of Key Spring 2026 Investor and Partnering Conferences NewcelX Ltd. (NASDAQ: NCEL) ("NewcelX" or the "Company"), a clinical-stage cell therapy company advancing transformative treatments for chronic...
NewcelX Ltd. has updated its corporate presentation ahead of key spring 2026 investor conferences, emphasizing its focus on Type 1 Diabetes cell therapy. The presentation highlights recent scientific advancements and the addition of experienced leaders to its team. The company aims to engage with investors and partners to advance its clinical programs.
Read more →NCEL▲ +13.7%on this news
NewcelX Announce Positive Results from International Collaborative Study Exploring Advanced Biomaterial Approaches for Stem Cell-Derived Islet Delivery in Type 1 Diabetes Without Immune Suppression NewcelX Ltd. (Nasdaq: NCEL) ("NewcelX" or the "Company"), a clinical-stage biotechnology company advancing regenerative medicine solutions, today...
NewcelX Ltd. reported positive results from an international study on advanced biomaterial strategies for stem cell-derived islet delivery in Type 1 Diabetes. The research demonstrated that engineered scaffolds with extracellular matrix support islet function effectively. This aligns with NewcelX's goal of developing cell therapies that eliminate the need for immunosuppression.
Read more →NCEL▲ +13.7%on this news
NewcelX Announce Positive Results from International Collaborative Study Exploring Advanced Biomaterial Approaches for Stem Cell-Derived Islet Delivery in Type 1 Diabetes Without Immune Suppression Zurich, Switzerland -
NewcelX has announced positive results from an international study investigating advanced biomaterial approaches for stem cell-derived islet delivery in type 1 diabetes. The research, conducted in collaboration with several universities and organizations, demonstrated that engineered scaffolds incorporating extracellular matrix from a decellularized human pancreas could support islet function effectively. The study's findings align with NewcelX's focus on developing scalable stem cell therapies aimed at treating type 1 diabetes without the need for chronic immune suppression. This progress is supported by additional funding from organizations such as the Australian Foundation for Diabetes Research and Breakthrough T1D.
Read more →NCEL▲ +6.7%on this news
NewcelX Appoints Dr. Julien Boisdron, a Swiss Big Pharma Leader in Diabetes Innovation, to Its Scientific Advisory Board NewcelX Ltd. (NASDAQ: NCEL) ("NewcelX"), a biotechnology company developing cell-based and small-molecule therapies for neurodegenerative and...
NewcelX Ltd. has appointed Dr. Julien Boisdron to its Scientific Advisory Board, enhancing its focus on diabetes innovation. Dr. Boisdron brings over two decades of experience in diabetes care and will provide strategic guidance for NewcelX's lead program, IsletRx, aimed at treating Type 1 Diabetes. His expertise is expected to support the company as it advances toward clinical trials.
Read more →NCEL▲ +6.7%on this news
NewcelX Appoints Dr. Julien Boisdron, a Swiss Big Pharma Leader in Diabetes Innovation, to Its Scientific Advisory Board Zurich, Switzerland and Ness Ziona, Israel - January 5th, 2026 - NewcelX Ltd. (Nasdaq: NCEL) ("Newc
NewcelX Ltd. has appointed Dr. Julien Boisdron, an experienced diabetes expert from a Swiss big pharma, to its Scientific Advisory Board. Dr. Boisdron will provide strategic guidance for NewcelX’s stem-cell-derived islet cell therapy, IsletRx, aimed at treating insulin-dependent Type 1 Diabetes. His background in diabetes care and connected-care innovation is expected to advance the program towards clinical trials and future commercialization. This move strengthens NewcelX's leadership in metabolic and regenerative medicine.
Read more →NCEL▼ -21.8%on this news
NewcelX Expands Intellectual Property Footprint with Publication of DOXA Patent Application in China NewcelX Ltd. (Nasdaq: NCEL), a next-generation biotechnology company developing advanced cell-therapy and neuroscience-driven therapeutics, today...
NewcelX Ltd. has published a significant international patent application in China, covering a new class of compounds for treating neurological diseases. This expansion enhances the company's small-molecule portfolio and supports its strategy in advancing therapeutic innovations. The DOXA program aims to address various CNS-related conditions, linking sleep regulation with metabolic health.
Read more →NCEL▼ -21.8%on this news
NewcelX Expands Intellectual Property Footprint with Publication of DOXA Patent Application in China Publication in key market advances NewcelX's global IP strategy across Asia and supports the Company's expanding positi
NewcelX Ltd. has announced the publication of a significant international patent application in China for its DOXA compounds, which are designed for treating neurological and metabolic diseases. This development enhances NewcelX's global intellectual property strategy and supports its efforts in advancing therapeutic innovation in areas like sleep-wake disorders and neurodegeneration. The DOXA patent expands the company's small-molecule portfolio and is part of its long-term goal to build a diverse therapeutic pipeline. The publication also paves the way for potential registration in Hong Kong, adding strategic protection for future commercialization.
Read more →NCELNewcelX Strengthens Scientific Advisory Board with Appointment of Jeremy Shefner, MD, PhD, Chief Medical Officer at the Barrow Neurological Institute Zurich, Switzerland and Ness Ziona, Israel
NewcelX has appointed Prof. Jeremy Shefner, MD, PhD, as a member of its Scientific Advisory Board. Prof. Shefner, a respected neurologist and Chief Medical Officer at Barrow Neurological Institute, will contribute his expertise in neuromuscular disorders and ALS research. His appointment is seen as a strengthening move for NewcelX as it develops therapies targeting neurodegenerative diseases. The company combines advanced stem-cell technologies with a focus on neuroscience to deliver innovative treatments.
Read more →NCELNewcelX Strengthens Scientific Advisory Board with Appointment of Jeremy Shefner, MD, PhD, Chief Medical Officer at the Barrow Neurological Institute NewcelX Ltd. (Nasdaq: NCEL) ("NewcelX" or "the Company"), a clinical-stage biotechnology company developing cell-based and small-molecule therapies...
NewcelX Ltd. has appointed Prof. Jeremy Shefner, MD, PhD, to its Scientific Advisory Board. Prof. Shefner, a leading neurologist in ALS research, will provide strategic guidance on the company's programs, particularly in ALS clinical development. His expertise is expected to enhance NewcelX's capabilities in addressing neurodegenerative diseases.
Read more →NCEL▼ -11.7%on this news
NewcelX Announces Scientific Leadership with the Head of Division of Medical Neurosciences at the Department of Neurology at Hadassah, Prof. Tamir Ben-Hur on Its Scientific Advisory Board NewcelX Ltd. (NASDAQ: NCEL) ("NewcelX" or the "Company"), a biotechnology company advancing transformative therapies for neurodegenerative and...
NewcelX Ltd. has appointed Professor Tamir Ben-Hur to its Scientific Advisory Board. Prof. Ben-Hur, a leading neurologist, brings significant expertise in neuroimmunology and regenerative medicine. His involvement is seen as a strong endorsement of NewcelX's mission to develop innovative therapies for neurodegenerative diseases. The merger with Kadimastem Ltd. is expected to enhance their capabilities in cell therapy.
Read more →NCEL▲ +10%on this news· ran to -22% by day 3shared move
NewCelX CEO Issues Letter to Shareholders Zurich, Switzerland
NewCelX Ltd., a biopharmaceutical company, issued a letter to shareholders detailing its strategic outlook and upcoming clinical milestones. The company aims to deliver innovative therapies for neurodegenerative and metabolic diseases, with a focus on ALS and diabetes. CEO emphasizes the strength of its financial position and the potential of its pipeline in achieving significant breakthroughs. However, investors are reminded of the inherent risks in clinical trials and regulatory approvals. NewCelX is preparing for an accelerated development phase over the next year.
Read more →NCEL▲ +10%on this news· ran to -22% by day 3shared move
NewcelX CEO Issues Letter to Shareholders NewcelX Ltd. (Nasdaq: NCEL), a Swiss clinical-stage biopharmaceutical company developing cell-based and small-molecule therapies for...
NewcelX Ltd. has issued a letter to shareholders outlining its strategic vision and upcoming milestones. The company is focusing on developing innovative therapies for neurodegenerative and metabolic diseases, with significant clinical trials planned for the next year. Financially, NewcelX is well-capitalized following a merger and recent funding, positioning it for growth and value creation.
Read more →NCEL▼ -29.5%on this news· ran to -43% by day 3shared move
NewCelX Provides Business and Strategic Roadmap Update Following Closing of Merger with NLS Pharmaceutics Ltd. Zurich, Switzerland
NewCelX Ltd. has announced a business and strategic roadmap update following its merger with NLS Pharmaceutics. The company focuses on developing cell-based and small-molecule therapies targeting neurodegenerative and metabolic diseases, including ALS and Type 1 Diabetes. An investor presentation has been made available to the public, outlining the company’s plans and expectations regarding future growth and clinical trials. However, the announcement also includes forward-looking statements that highlight various risks and uncertainties that could affect the company's future performance.
Read more →NCEL▼ -29.5%on this news· ran to -43% by day 3shared move
NewcelX Provides Business and Strategic Roadmap Update Following Closing of Merger with NLS Pharmaceutics Ltd. NewcelX Ltd. (Nasdaq: NCEL) ("NewcelX" or the "Company"), a Swiss clinical-stage biopharmaceutical company developing cell-based and small-molecule...
NewcelX Ltd. has provided a strategic roadmap update following its merger with NLS Pharmaceutics. The company focuses on developing cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. An investor presentation is now accessible on their website, outlining future plans and potential challenges in clinical trials and regulatory approvals.
Read more →NCELNLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Completion of Merger Combined Company Re-Named NewcelX Ltd., to Commence Trading on the Nasdaq Capital Market on
NLS Pharmaceutics Ltd. and Kadimastem Ltd. have successfully completed their merger, forming NewcelX Ltd., which will start trading on the Nasdaq Capital Market under ticker symbol 'NCEL' on October 31, 2025. The merger consolidates their efforts in cell therapy and drug development, particularly targeting debilitating diseases such as ALS and diabetes. NewcelX's leadership emphasized the potential for transformative therapies and expressed gratitude towards shareholders for their support during this transition. As part of the merger, shareholders will receive contingent value rights related to future asset dispositions.
Read more →NCELNLS Pharmaceutics Expands CNS Pipeline With AEX-6xx Series Developed by Aexon Labs DOXA Platform Expansion Strengthens Cognitive, Arousal, and Neuroprotective Programs Supported by Solid Cash Position and Strategic Fundi
NLS Pharmaceutics, in collaboration with Aexon Labs, announced the expansion of their CNS pipeline with the introduction of the AEX-6xx series via the DOXA platform. This new series focuses on enhancing cognitive functions, arousal stability, and neuroprotection, notably in conditions like Parkinson's disease. The companies disclosed a robust financial position due to recent fundraising efforts, enabling them to pursue new clinical studies and partnerships, while preparations are underway for a unified brand identity following their merger to form NewCelX.
Read more →NCELNLS Pharmaceutics and Kadimastem Highlight Continued BIRD Foundation Support for ITOL-102 Diabetes Program Following Merger Zurich, Switzerland
NLS Pharmaceutics and Kadimastem have highlighted the ongoing support from the BIRD Foundation for their ITOL-102 cell therapy program following their merger. The collaboration aims to develop a treatment for Type 1 Diabetes that eliminates the need for permanent immunosuppression. The BIRD Foundation's investment emphasizes the commitment to translating scientific advancements into practical applications. The merger is expected to bolster the capabilities and pipeline of the newly formed company, NewCelX, as it moves forward with the therapy's development.
Read more →NCELSTATUTEN der NewcelX AG NewcelX SA NewcelX Ltd (die "Gesellschaft") ARTICLES OF ASSOCIATION of NewcelX AG NewcelX SA NewcelX Ltd (the "Company") I. Firma, Sitz, Dauer und Zweck der Gesellschaft Art. 1 - Firma, Sitz, Daue
The article outlines the Articles of Association of NewcelX AG, NewcelX SA, and NewcelX Ltd, indicating that the companies are established as stock corporations in Kloten, Switzerland for an indefinite duration. Their primary purpose includes research and development in pharmaceutical and related fields, along with the capacity to acquire licenses and manage properties. The capital framework allows for increases and decreases in share capital, providing flexibility for future financial structuring.
Read more →NCELNLS Pharmaceutics and Kadimastem Announce Completion of Material Conditions Precedent for Merger Transaction and Delisting Date of Kadimastem's Shares Zurich, Switzerland and Ness Ziona, Israel
NLS Pharmaceutics and Kadimastem have announced that all material conditions precedent for their merger transaction have been completed, allowing them to proceed with the merger. The final delisting of Kadimastem's shares from the Tel Aviv Stock Exchange is scheduled to take place, facilitating a transition to a new entity named NewCelX Ltd. This combined company will begin trading under the ticker symbol NCEL on the Nasdaq Capital Market starting October 31, 2025. Shareholders of Kadimastem will receive NLS common shares in exchange, with trading expected to start shortly after the completion of the merger.
Read more →NCELNLS Pharmaceutics and Kadimastem Announce Strategic Collaboration between Kadimastem and TargetGene to Advance Next-Generation Gene-Edited Cell Therapies The collaboration will progress under the combined company, NewCel
NLS Pharmaceutics and Kadimastem have announced a strategic collaboration with TargetGene to enhance gene-edited cell therapies. This partnership, to be executed under the new merged entity NewCelX, will utilize Kadimastem's cell therapy platforms alongside TargetGene's gene-editing technology. The collaboration seeks to optimize the development of scalable and commercially viable cell-based treatments, especially for conditions such as ALS and diabetes. It represents a key move in the companies' efforts to provide transformative solutions for patients worldwide.
Read more →NCELNLS and Kadimastem Announce Receipt of Nasdaq Approval; Merger Expected to Close on
NLS Pharmaceutics Ltd. has received approval from the Nasdaq for its merger with Kadimastem Ltd., anticipated to close on October 30, 2025. Following the merger, the combined company will operate under the name NewCelX Ltd., and commence trading the next day. Kadimastem shareholders will hold approximately 84.4% of the new entity, while NLS shareholders will retain around 15.6%. This merger aims to advance their collaborative clinical development programs for neurodegenerative diseases and diabetes.
Read more →NCELKadimastem Ltd. Interim Condensed Financial Statements as of
Kadimastem Ltd. has published its interim condensed financial statements for the first half of 2025, revealing an operating loss of over $11 million. The financial report indicates a decrease in cash reserves and a troubling increase in accumulated deficits, raising concerns about the company’s financial stability. Additionally, the current liabilities far exceed current assets, highlighting potential liquidity challenges. The company acknowledges that it must secure resources to continue its operations and planned financing efforts include loans from investors and equity sales.
Read more →NCELNLS PHARMACEUTICS LTD. UNAUDITED INTERIM CONDENSED FINANCIAL STATEMENTS AS OF JUNE 30, 2025 AND FOR THE SIX MONTHS ENDED JUNE 30, 2025 AND 2024 NLS PHARMACEUTICS LTD. UNAUDITED INTERIM CONDENSED FINANCIAL STATEMENTS Page
NLS Pharmaceutics Ltd. has released its unaudited interim condensed financial statements for the six months ended June 30, 2025. The company reported significant losses, with a net loss attributable to common shareholders reaching $4,192,877, which is notably higher than the previous year. Despite an increase in current assets and cash position, operating expenses have risen, especially due to general administrative costs and merger transaction costs. This ongoing financial struggle highlights the challenges faced by the company as it progresses in the development of its biopharmaceutical products.
Read more →NCELNLS Pharmaceutics Shareholders Approve Merger with Kadimastem and Related Proposals at Extraordinary General Meeting Vote clears final corporate milestone, paving the way for the closing of the merger and the combined co
NLS Pharmaceutics shareholders have approved a merger with Kadimastem at an Extraordinary General Meeting, clearing the final milestone for the merger. The approval sets the stage for listing the newly formed company, NewCelX Ltd., on Nasdaq under the ticker NCEL. This merger aims to unify Kadimastem's cell therapy pipeline with NLS's expertise in CNS disorders, potentially enhancing the combined company's market position and operational effectiveness. Subject to final Nasdaq approval, the merger intends to drive long-term growth and address unmet medical needs.
Read more →NCELKadimastem and NLS Pharmaceutics Announce Effectiveness of SEC Registration Statement in Connection with Proposed Merger Zurich, Switzerland and Ness Ziona, Israel
Kadimastem and NLS Pharmaceutics have announced the effectiveness of their SEC registration statement related to their proposed merger. This approval marks the final federal regulatory requirement needed to close the merger, which is anticipated to unite Kadimastem's cell therapy platforms with NLS's small-molecule therapies. The new entity will be named NewCelX Ltd., and both companies believe the merger will position them strategically in the biotechnology space to better serve patients with unmet medical needs. An extraordinary general meeting is scheduled for September 29, 2025, to finalize the merger process.
Read more →NCELNLS Pharmaceutics and Kadimastem announce a Hong Kong Patent Covering Cell-Selection and Enrichment Technology for IsletRx for Diabetes Patients - Patent grant broadens IP protection in Asia and complements prior patents
NLS Pharmaceutics and its merger partner Kadimastem announced the granting of a Hong Kong patent for Kadimastem's cell-selection and enrichment technology used in the IsletRx therapy, which aims to treat insulin-dependent diabetes. This patent enhances their existing portfolio, which includes patents granted in Europe, the US, and India. The company acknowledges the significant health impact of diabetes in Hong Kong, making the expansion of intellectual property protection a strategic priority for both their current developments and long-term goals. The new patent is seen as critical as the companies advance towards clinical application of their technology.
Read more →NCELSEVENTH AMENDMENT TO AGREEMENT OF MERGER AND PLAN OF REORGANIZATION This Seventh Amendment to Agreement of Merger and Plan of Reorganization (this " Amendment ") is made and entered into as of
The Seventh Amendment to the Agreement of Merger and Plan of Reorganization between Kadimastem Ltd., NLS Pharmaceutics Ltd., and NLS Pharmaceuticals (Israel) Ltd. was executed on August 29, 2025. This amendment extends the Termination Date of the merger agreement from August 31, 2025, to October 31, 2025. All other terms of the initial agreement remain in effect. The amendment was executed by authorized signatories from each of the parties involved.
Read more →NCELExecution Version EXCHANGE AGREEMENT THIS EXCHANGE AGREEMENT (this " Agreement "), dated as of
NLS Pharmaceutics Ltd. has entered into an exchange agreement with Alpha Capital Anstalt to exchange a warrant for common shares. The agreement specifies the exchange of one warrant for 100,000 shares to be issued within one trading day. This transaction is conducted under an exemption from registration, reflecting the company's compliance with regulatory requirements. Both parties have agreed on terms that ensure the rights of the issued shares align with previous agreements.
Read more →NCELSIXTH AMENDMENT TO AGREEMENT OF MERGER AND PLAN OF REORGANIZATION This Sixth Amendment to Agreement of Merger and Plan of Reorganization (this " Amendment ") is made and entered into as of
The Sixth Amendment to the Agreement of Merger and Plan of Reorganization was made among Kadimastem Ltd., NLS Pharmaceutics Ltd., and NLS Pharmaceuticals (Israel) Ltd. on July 18, 2025. This amendment includes updated provisions regarding the calculation of closing indebtedness and cash, as well as the definition of fully diluted shares. It signifies ongoing adjustments and refinements to the merger agreement, emphasizing the parties' commitment to the regulatory process. The agreement remains in effect in its amended form without further modifications.
Read more →NCELNLS Pharmaceutics Highlights Continued Progress in iTOL-102 Diabetes Program as BIRD Foundation Approves Additional Milestone Payment to Kadimastem and iTolerance for Continued Co-Development of Type 1 Diabetes Cell Ther
NLS Pharmaceutics has announced continued progress in its iTOL-102 diabetes program following approval of an additional milestone payment from the BIRD Foundation. The funding supports the co-development efforts between NLS, Kadimastem, and iTolerance, and comes after a successful Pre-IND meeting with the FDA. The collaboration aims to develop a novel cell therapy that could potentially cure Type 1 diabetes without the need for lifelong immunosuppression. This demonstrates confidence in the therapeutic advancements being made in the program, which is preparing for clinical trials.
Read more →NCELFIFTH AMENDMENT TO AGREEMENT OF MERGER AND PLAN OF REORGANIZATION This Fifth Amendment to Agreement of Merger and Plan of Reorganization (this "Amendment") is made and entered into as of
NLS Pharmaceutics Ltd. and Kadimastem Ltd. have entered into a Fifth Amendment to their Merger and Plan of Reorganization. The amendment, effective from July 1, 2025, extends the termination date of the merger agreement from June 30, 2025, to August 31, 2025. This change reinforces the ongoing commitment between the parties while keeping the original agreement intact. As per the terms, all prior amendments remain in force, ensuring comprehensive governance of the merger process.
Read more →NCELAMENDMENT TO THE SECURITIES PURCHASE AGREEMENT This Amendment to the Securities Purchase Agreement (this " Amendment ") is dated as of
NLS Pharmaceutics Ltd. has amended its Securities Purchase Agreement dated March 27, 2025, to facilitate a Subsequent Closing. In this amendment, the company will issue Preferred Participation Certificates (PPCs) instead of Preferred Shares due to a shortfall in the authorized shares. The change allows the Subsequent Closing to proceed, with the PPCs retaining the same rights as Preferred Shares. Additionally, the company is required to file a resale registration statement for the shares involved within a specified timeframe.
Read more →NCELNLS Pharmaceutics CEO Issues Letter to Shareholders ZURICH, June 16,2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (NASDAQ: NLSP ), a Swiss clinical-stage biopharmaceutical company focused on developing innovative therapies
NLS Pharmaceutics Ltd. has issued a letter to shareholders detailing significant milestones achieved, including successfully raising over $6 million and indicating progress on a merger with Kadimastem. The company aims to complete this merger by early Q3 2025, which is expected to enhance its ability to provide comprehensive treatment options for diabetes and other CNS disorders. NLS Pharmaceutics highlighted a debt-free status and increased cash runway as critical to its ongoing research and development efforts.
Read more →NCELTo the shareholders of NLS Pharmaceutics Ltd., Zurich, Switzerland Zurich
NLS Pharmaceutics Ltd. has called for an ordinary shareholders' meeting scheduled for June 30, 2025. The meeting will address several agenda items including the re-election of the independent proxy KBT Treuhand AG and the approval of financial statements for the business year 2024, which reflect significant losses. Additionally, a compensation report will be reviewed and several members of the Board of Directors will stand for re-election. The company's financial outlook appears challenging given the reported operating loss and accumulated debts.
Read more →NCELFOURTH AMENDMENT TO AGREEMENT OF MERGER AND PLAN OF REORGANIZATION This Fourth Amendment to Agreement of Merger and Plan of Reorganization (this "Amendment") is made and entered into as of
The Fourth Amendment to the Agreement of Merger and Plan of Reorganization between Kadimastem Ltd. and NLS Pharmaceutics Ltd. indicates further adjustments to their merger terms. Amendments include changes to share conversions, financial estimates, and management structures. These modifications aim to facilitate a smoother merger process while addressing potential financial metrics and leadership arrangements. The ongoing amendments reflect an adaptive strategy amidst evolving circumstances surrounding the merger deal.
Read more →NCELAMENDMENT NO. 3 TO THE AGREEMENT OF MERGER AND PLAN OF REORGANIZATION This Amendment is made as of
The article discusses Amendment No. 3 to the Agreement of Merger and Plan of Reorganization involving Kadimastem Ltd., NLS Pharmaceutics Ltd., and NLS Pharmaceuticals (Israel) Ltd. This amendment aims to clarify the terms of the existing agreement, initially established in November 2024 and previously amended in early 2025. The document includes signatures from key executives of the involved parties, confirming the execution of the amendment.
Read more →NCELNLS Pharmaceutics Announces Positive Results from Study KO-943 Demonstrating Mazindol Reduces Fentanyl- Induced Reward in Animal Models Non-opioid, multi-mechanism profile positions Mazindol as a differentiated asset in
NLS Pharmaceutics announced positive results from Study KO-943, demonstrating Mazindol's efficacy in reducing fentanyl-induced conditioned place preference in animal models. This non-opioid treatment approach could address the fentanyl crisis contributing to opioid-related overdose deaths in the U.S. The findings support Mazindol's unique multi-target profile, potentially positioning it as a safer alternative to traditional opioid therapies. The company's ongoing funding efforts will facilitate the development of Mazindol alongside other clinical assets post-merger with Kadimastem Ltd.
Read more →NCELto Form 6-K (File No. 001-39957) filed on
NLS Pharmaceutics Ltd. has entered into a Securities Purchase Agreement dated March 26, 2025, with designated purchasers to sell securities. This agreement outlines the terms for the purchasers to acquire company securities under certain regulatory exemptions. The sale aims to generate funds for the company, highlighting its growth strategy amidst regulatory considerations.
Read more →NCELNEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FRO
The article discusses a common share purchase warrant issued by NLS Pharmaceutics Ltd. The warrant allows the holder to purchase shares at a certain price but emphasizes that the securities have not been registered with the SEC or any state regulators. Consequently, restrictions may apply to their sale or offer. The article details the terms of exercising the warrant and the conditions under which it may be executed, alongside complexities involving pricing adjustments.
Read more →NCELNLS Pharmaceutics CEO Issues Letter to Shareholders ZÜRICH, Switzerland
NLS Pharmaceutics has issued a letter to shareholders, highlighting significant achievements and a strategic merger with Kadimastem to enhance its pipeline in CNS disorders and diabetes treatment. The merger aims to establish a Nasdaq-traded entity, pending regulatory approvals and shareholder consent. NLS Pharmaceutics is also partnering on innovative therapies, such as the pre-IND for a Type 1 Diabetes treatment. Additionally, preparations for a Phase IIa trial of AstroRx for ALS are in progress, reflecting the company's commitment to advancing its research and development.
Read more →NCELNLS Pharmaceutics Announces New Preclinical Data for AEX-2, Expanding the Therapeutic Potential of its Non-Sulfonamide Dual Orexin Receptor Agonist Platform Z rich, Switzerland
NLS Pharmaceutics announced promising preclinical data for AEX-2, a first-in-class dual orexin receptor agonist, developed to address narcolepsy and various neurological disorders. Collaborative efforts with Aexon Labs have highlighted AEX-2's potential safety profile and targeted therapeutic effects, showcasing its ability to stabilize sleep-wake cycles. With plans to progress into IND-enabling studies in 2025, the company aims to initiate first-in-human clinical trials by 2026. Upcoming presentations at the ASCP Annual Meeting are expected to further detail these findings.
Read more →NCELKadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment Companies Advance Collaborative Clinical Development of iTOL-102: A Potential Cure for Diabetes Without the N
Kadimastem Ltd. and iTolerance Inc. announced the successful completion of a pre-IND meeting with the FDA regarding their collaboration on iTOL-102, a potential Type 1 Diabetes treatment that may not require lifelong immune suppression. The meeting provided essential feedback for further clinical development, which will include a safety toxicology study and preparations for a first-in-human trial. The companies highlighted the therapeutic potential and breakthrough nature of iTOL-102, as it combines stem cell-derived pancreatic islets with an immunomodulator. They are optimistic about regulatory approvals paving the way for commercialization.
Read more →NCELNLS Pharmaceutics and Kadimastem Unveil Multi-Target Approach to Diabetes, Expanding Beyond GLP-1 Therapies Revolutionizing Diabetes Treatment : Introduction of cutting-edge, multi-targeted innovation to transform diabet
NLS Pharmaceutics and Kadimastem are announcing a planned merger to enhance their approach to diabetes treatment by introducing a multi-target innovation named DOXA. This new therapy aims to address systemic and neurological complications of diabetes, extending beyond conventional GLP-1 receptor agonists. The merger is expected to combine their respective strengths in cell therapy and pharmaceutical innovation, positioning them as leaders in the evolving landscape of diabetes treatment. However, the success of this merger and the introduction of DOXA hinges on regulatory approvals and successful clinical trials.
Read more →NCELKadimastem Shareholders Approved the Merger with NLS Pharmaceutics ZURICH, SWITZERLAND and
Kadimastem's shareholders have approved the merger with NLS Pharmaceutics, moving towards creating a combined biotechnology company focused on therapies for neurodegenerative diseases and diabetes. This approval is seen as a significant milestone for both companies, indicating confidence in the expected value and synergies from the merger. The involvement of both companies' leadership suggests a strong commitment to advancing innovative healthcare solutions. NLS Pharmaceutics is planning a future meeting for final approval, highlighting the ongoing collaborative efforts in this venture.
Read more →NCELAMENDMENT TO THE AGREEMENT OF MERGER AND PLAN OF REORGANIZATION This Amendment, dated
Kadimastem Ltd. and NLS Pharmaceutics Ltd. have amended their merger agreement dated November 4, 2024, to clarify terms related to Beneficial Ownership Limitation. This amendment allows holders of shares who exceed the ownership limit to receive pre-funded warrants instead of common stock. The decision aims to ensure that all parties maintain compliance with ownership constraints while facilitating the merger process.
Read more →NCELNLS Pharmaceutics Announces the Submission of Three Research Abstracts to the 2025 ASCP Annual Meeting Zurich, Switzerland
NLS Pharmaceutics Ltd., a Swiss clinical-stage biopharmaceutical company, announced the submission of three research abstracts for the 2025 ASCP Annual Meeting. Scheduled from May 27 to May 30, 2025, in Scottsdale, Arizona, the meeting focuses on advancements in neuropsychopharmacology. The submitted abstracts cover innovative therapeutic solutions for fentanyl dependence, narcolepsy, and diabetes-related neurological disorders, highlighting the company's commitment to tackling unmet medical needs in these areas.
Read more →NCELNLS Pharmaceutics Announces the Launch of a Preclinical Program for Mazindol ER in the Treatment of Fentanyl Dependence Centers for Disease Control and Prevention (the "CDC") reported 105,007 drug overdose deaths - with
NLS Pharmaceutics has launched a preclinical program to investigate Mazindol ER as a treatment for fentanyl dependence, a significant global health issue exacerbated by the opioid epidemic. The initiative aims to explore Mazindol's potential as a non-opioid alternative for managing opioid addiction through its action on multiple neurotransmitter pathways. This program could provide a much-needed solution amid the rising number of drug overdose deaths attributed to synthetic opioids like fentanyl. The company anticipates completing the preclinical study within 12-18 months, pending favorable results to advance regulatory submissions.
Read more →NCELKadimastem Calls for a Special General Meeting of Shareholders to Approve the Merger with NLS Kadimastem Approaches Final Steps for Securing Merger Completion ZURICH, SWITZERLAND and NESS ZIONA, ISRAEL- January 16 th 202
Kadimastem has announced a special general meeting for shareholders to approve its merger with NLS Pharmaceutics, a crucial step toward completion. This comes after NLS successfully raised $500,000 as part of a $1 million funding round, significantly above market price. The merger aims to form a Nasdaq-traded biotechnology company with a strong pipeline of innovative therapies. NLS has also filed a registration statement with the SEC regarding the proposed merger, showcasing its commitment to advancing biotechnology solutions.
Read more →NCELNLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce the Initial Closing of $500,000 of the Previously Announced $1 Million Fundraising by NLS Following its Extraordinary General Meeting at a Share Price of $3.10, Represe
NLS Pharmaceutics Ltd. and Kadimastem Ltd. have announced the successful initial closing of $500,000 of a $1 million fundraising effort, following NLS's extraordinary general meeting. The share price for the financing was set at $3.10, which is 48% higher than the market closing price prior to the meeting. This fundraising is intended to support the proposed merger between the two companies, aimed at creating a robust biopharmaceutical entity with advanced product candidates. The merger's completion remains contingent on securing necessary shareholder approvals.
Read more →NCELNLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Filing of F-4 Registration Statement with the SEC Ahead of Proposed Merger The proposed transaction will create a Nasdaq-traded, biotechnology company with product cand
NLS Pharmaceutics Ltd. and Kadimastem Ltd. have filed a Registration Statement with the SEC regarding their planned merger, which will lead to a combined company focused on biotechnology and cell therapy. This merger, supported by over 40% of shareholder commitments, is expected to enhance market presence and shareholder value. The merger will be executed through a reverse triangular structure in which Kadimastem becomes a wholly owned subsidiary of NLS, with a significant majority of post-merger shares going to Kadimastem shareholders. Both companies express optimism about their innovative technology and continued development of therapies for various disorders.
Read more →NCELTo the shareholders of NLS Pharmaceutics Ltd., Zurich, Switzerland Zurich, 23 December 2024 Invitation to the Extraordinary Shareholders' Meeting of NLS Pharmaceutics Ltd., Zurich, Switzerland Dear Shareholder, The board
NLS Pharmaceutics Ltd. has announced an extraordinary shareholders' meeting set for January 14, 2025. The meeting will cover significant agenda items including a proposed nominal value reduction of shares and potential capital increases. The board intends to manage company capital efficiently by reallocating the reduced nominal values to reserves. Important voting instructions and adjustments based on shareholder decisions are also outlined.
Read more →NCELNLS Pharmaceutics and Kadimastem Announce the Submission of a Request by Kadimastem and iTolerance, Inc. for an FDA Pre-IND Meeting for an Innovative Breakthrough Type 1 Diabetes Treatment This submission comes after suc
NLS Pharmaceutics and Kadimastem have submitted a request for a Pre-IND meeting with the FDA to discuss iTOL102, an innovative treatment for Type 1 Diabetes. This product combines allogenic stem cell-derived islets with an immunomodulator, potentially providing a breakthrough solution that may negate the need for lifelong immunosuppression. The submission follows a successful initial meeting with regulators and represents a significant milestone toward clinical trials. Additionally, NLS Pharmaceutics is optimistic about their pending merger with Kadimastem, which could positively impact their development pipeline.
Read more →NCELNLS Pharmaceutics CEO Issues Letter to Shareholders Z rich, Switzerland
NLS Pharmaceutics has issued a letter to shareholders detailing significant advancements in their Dual Orexin Receptor Agonist platform and an impending merger with Kadimastem Ltd. CEO Alex Zwyer highlighted the recent financial accomplishments, including compliance with Nasdaq continued listing requirements and a successful fundraising effort. The preclinical studies for their compounds AEX-41 and AEX-2 show promise in treating narcolepsy, with results expected by year-end. NLS is focused on maximizing shareholder value and leveraging strategic opportunities in neurodegenerative disease therapies.
Read more →NCELTo the shareholders of NLS Pharmaceutics Ltd., Zurich, Switzerland Zurich, 16 December 2024 Invitation to the Extraordinary Shareholders' Meeting of NLS Pharmaceutics Ltd., Zurich, Switzerland Dear Shareholder, The board
NLS Pharmaceutics Ltd. has invited shareholders to an extraordinary meeting on January 7, 2025, to discuss several important agenda items. The proposals include raising capital through a private investment in public equity (PIPE) transaction, which may involve issuing up to 322,580 new common shares at a price of USD 3.10 each. Additionally, the company aims to convert preferred shares into common shares to enhance financial flexibility. Shareholder approval is sought for these capital increases and the overall restructuring plan.
Read more →NCELNLS Pharmaceutics Announces Promising Preclinical Data for First-in-Class Non-Sulfonamide, Dual Orexin Receptor Agonists for the Potential Treatment of Narcolepsy and Neurological Disorders Z rich, Switzerland
NLS Pharmaceutics announced encouraging preclinical data on its dual orexin receptor agonists, AEX-41 and AEX-2, which could offer a new treatment for narcolepsy and neurological disorders. These agents target orexin-1 and orexin-2 receptors while inhibiting cathepsins, presenting a dual-action therapeutic approach. The ongoing preclinical study at a prominent neuroscience center aims to investigate their effects in neuroinflammation models. The company has plans to submit an Investigational New Drug application in the next few years, further highlighting its commitment to research and development.
Read more →NCELNLS Pharmaceutics Highlights Innovative Preclinical Program for First-in-Class Non-Sulfonamide Dual Orexin Receptor Agonists (DOXA) in Narcolepsy and Neurological Disorders Z rich, Switzerland
NLS Pharmaceutics Ltd. has highlighted its preclinical program for dual orexin receptor agonists (DOXA) aimed at treating narcolepsy and other neurological disorders. The two compounds, AEX-41 and AEX-2, are designed to target orexin receptors and are expected to offer superior therapeutic outcomes compared to existing treatments. Ongoing studies are taking place at the Centre for Neuroscience Research of Lyon, utilizing an orexin knockout mouse model. The company plans to disclose initial results of its studies in December 2024 and is exploring potential applications in other neurodegenerative conditions.
Read more →NCELSTATUTEN ARTICLES OF ASSOCIATION der of NLS Pharmaceutics AG NLS Pharmaceutics AG NLS Pharmaceutics SA NLS Pharmaceutics SA NLS Pharmaceutics Ltd NLS Pharmaceutics Ltd (die "Gesellschaft") (the "Company") I. Firma, Sitz,
NLS Pharmaceutics AG has updated its Articles of Association, outlining its structure and purpose. The company, based in Kloten, focuses on research and development across pharmaceutical and related fields. It has clarified its capital structure, with a capital amounting to CHF 1,841,507.20, which includes common and preferred shares. Moreover, provisions for future capital increases and share allocations have been established.
Read more →NCELKadimastem Ltd. Financial Statements as of
Kadimastem Ltd. has released its financial statements for the period ending December 31, 2023. The audits reveal significant recurring losses, leading to concerns about the company's sustainability as a going concern. Moreover, the company faces negative cash flows and a deficiency in equity, indicating financial distress. The auditors noted that these financial statements do not reflect any adjustments that may arise from the uncertainties related to the company's future operations.
Read more →NCELCategory: Notifications issued to company members Sub-category: Invitation to the General Meeting Publication date: SHAB 18.10.2024 Publicly viewable until: 18.12.2024 Publication number: UP04-0000006582 Publishing entit
NLS Pharmaceutics AG announced an extraordinary general meeting scheduled for November 8, 2024, aimed at discussing important restructuring measures. The board of directors invited shareholders to vote on agenda items concerning capital increases and amendments to the company’s articles. The restructuring is crucial for ensuring the company’s survival and eligibility for future financing and strategic transactions. The meeting will take place at Wenger Vieli AG in Zug, Switzerland, and details of the voting instructions will be provided to the shareholders.
Read more →NCELAGREEMENT OF MERGER AND PLAN OF REORGANIZATION BY AND AMONG NLS Pharmaceutics LTD. NLS PHARMACEUTICS (ISRAEL) LTD. and KADIMASTEM LTD. DATED AS OF NOVEMBER 4 , 2024 CONTENTS Page Article I THE MERGER 1.1 The Merger 2 1.2
NLS Pharmaceutics Ltd. and Kadimastem Ltd. have announced a merger agreement dated November 4, 2024. The merger will see NLS Pharmaceutics (Israel) Ltd. being absorbed, allowing for streamlined operations under the NLS Pharmaceutics brand. Key shareholders have expressed support for the transaction, highlighting confidence in its potential benefits. The agreement also includes provisions for contingency value rights for shareholders, linking future financial outcomes to subsequent asset sales.
Read more →NCELNLS Pharmaceutics and Kadimastem Enter into a Definitive Merger Agreement Zurich, Switzerland and Ness Ziona, Israel
NLS Pharmaceutics Ltd. and Kadimastem Ltd. have announced a merger agreement to combine their operations, focusing on developing neurodegenerative and diabetes treatments. The merger aims to enhance NLS's first-in-class Dual Orexin Agonist platform and Kadimastem's allogeneic cell therapy programs. The deal, which has been unanimously approved by both companies' boards, is pending shareholder approval and is expected to close in January 2025. Following the merger, NLS plans to divest some legacy assets while focusing on advancing the combined entity's product pipeline.
Read more →NCELNLS Pharmaceutics Ltd. Regains Full Compliance with Nasdaq Listing Requirements ZURICH, SWITZERLAND / ACCESSWIRE /
NLS Pharmaceutics Ltd. has announced that it has regained full compliance with Nasdaq listing requirements. This follows successful efforts to enhance its financial standing, including raising new capital and a reverse share split. The CEO, Alex Zwyer, expressed satisfaction with the news and the company's improved balance sheet, which have contributed to this favorable outcome. The company continues to focus on developing innovative therapies for complex central nervous system disorders.
Read more →NCELSTATUTEN der NLS Pharmaceutics AG NLS Pharmaceutics SA NLS Pharmaceutics Ltd (die "Gesellschaft") ARTICLES OF ASSOCIATION of NLS Pharmaceutics AG NLS Pharmaceutics SA NLS Pharmaceutics Ltd (the "Company") I. Firma, Sitz,
NLS Pharmaceutics AG has established its articles of association with provisions for its corporate structure, office location in Kloten, and indefinite duration. The company focuses on researching and developing pharmaceutical and biotechnological products, as well as acquiring intellectual property and licenses. It has a defined share capital of CHF 2,623,112, divided into registered common and preferred shares, and the board is authorized to increase this capital under specific terms. The articles specify provisions for managing pre-emptive rights and other governance matters.
Read more →NCELNLS PHARMACEUTICS LTD. UNAUDITED INTERIM CONDENSED FINANCIAL STATEMENTS AS OF JUNE 30, 2024 AND DECEMBER 31, 2023 AND FOR THE SIX MONTHS ENDED JUNE 30, 2024 AND 2023 NLS PHARMACEUTICS LTD. UNAUDITED INTERIM CONDENSED FIN
NLS Pharmaceutics Ltd. reported its unaudited interim financial statements for the six months ending June 30, 2024, revealing significant losses and a high accumulated deficit. The company incurred an operating loss of approximately $2.1 million and has only $0.6 million in cash and cash equivalents, which is insufficient to sustain operations for the next year. To address financial challenges, NLS is actively exploring various funding options, including private financing and potential strategic partnerships. However, substantial doubt exists regarding the company’s viability as a going concern beyond one year from the financial statement date.
Read more →NCELNLS Pharmaceutics Ltd. Announces Closing of Private Placement and Expected Compliance with Nasdaq Continued Listing Rules ZURICH, SWITZERLAND / ACCESSWIRE /
NLS Pharmaceutics Ltd. announced the closing of a private placement that raised $3.2 million through the issuance of common shares and warrants. The company also reported that it believes it has regained compliance with Nasdaq's minimum bid price requirement after its shares traded above $1.00 for ten consecutive days. Additionally, NLS stated it meets the stockholders' equity requirement for continued listing on the Nasdaq Capital Market due to recent financial activities. The securities were offered under specific exemptions from registration requirements and will not be sold in the U.S. without proper registration.
Read more →NCELTo the shareholders of NLS Pharmaceutics Ltd., Zurich, Switzerland Zurich, 10 September 2024 Invitation to the Extraordinary Shareholders' Meeting of NLS Pharmaceutics Ltd., Zurich, Switzerland Dear Shareholder, The boar
NLS Pharmaceutics Ltd. announced an extraordinary shareholders' meeting scheduled for September 18, 2024. The agenda includes a proposal for a capital increase to ensure compliance with Nasdaq listing requirements and convert outstanding debts into equity. This move highlights the company's efforts to stabilize its financial situation and potentially prepare for future financing. However, the exclusion of preferential rights for the new shares signals challenges in the current market position.
Read more →NCELTo the shareholders of NLS Pharmaceutics Ltd., Zurich, Switzerland Zurich, 26 August 2024 Invitation to the Extraordinary Shareholders' Meeting of NLS Pharmaceutics Ltd., Zurich, Switzerland Dear Shareholder, The board o
NLS Pharmaceutics Ltd. will hold an extraordinary shareholders' meeting on September 18, 2024, at Wenger Vieli AG in Zug, Switzerland. The meeting will focus on consolidating shares to meet Nasdaq listing requirements and includes a proposed capital increase of CHF 40.28. Shareholders must register by September 13, 2024, to participate in the vote. The agenda will also introduce a capital band, allowing for potential future capital increases.
Read more →NCELNLS Pharmaceutics and Kadimastem Announce Binding Term Sheet to Merge The proposed transaction will create a Nasdaq-traded, biotechnology company with product candidates in advanced stages of clinical development and foc
NLS Pharmaceutics and Kadimastem have announced a binding term sheet to merge, creating a Nasdaq-traded biotechnology company. The merger will allow Kadimastem to become a wholly owned subsidiary of NLS, with Kadimastem shareholders acquiring 85% of the merged entity. The transaction is subject to approval from the shareholders of both companies and regulatory bodies. The combined company is expected to enhance product development, especially in advanced cell therapies for neurodegenerative diseases and diabetes. This strategic collaboration aims to create significant synergies while providing long-term value to stakeholders.
Read more →NCELNLS Pharmaceutics AG NLS Pharmaceutics Announces Registered Direct Offering ZURICH, SWITZERLAND / ACCESSWIRE /
NLS Pharmaceutics Ltd. has announced a registered direct offering to sell 3,277,750 common shares at a price of $0.24 per share, anticipated to close around July 1, 2024. The company expects to raise approximately $786,660 in gross proceeds, which will be used for working capital, including advancing research and development initiatives. Wainwright & Co. is acting as the exclusive placement agent for this offering, which includes unregistered warrants for additional shares.
Read more →NCELNLS Pharmaceutics Announces Promising Preclinical Results for Parkinson's Disease Treatments Zurich, Switzerland
NLS Pharmaceutics announced promising preclinical results from studies targeting the A53T mutation of alpha-synuclein for Parkinson's Disease treatment. The compounds, part of a collaboration with Aexon Labs, exhibited positive effects on neurite outgrowth, indicating potential benefits for neuronal health. NLS plans to develop new chemical successors, AEX-230 and AEX-231, to further investigate their efficacy and safety. The results emphasize a focus on innovative therapies for patients with unmet medical needs in neurodegenerative conditions.
Read more →NCELNASDAQ PANEL GRANTS NLS PHARMACEUTICS' REQUEST FOR EXTENSION TO COMPLY WITH CONTINUED LISTING REQUIREMENTS." E xhibit 99.1 Nasdaq Panel Grants NLS Pharmaceutics' Request for Extension to Comply with Continued Listing Req
NLS Pharmaceutics has received an extension from the Nasdaq Hearings Panel to comply with continued listing requirements, specifically regarding its minimum bid price and stockholders' equity. The company must meet these requirements by October 14, 2024. NLS had previously faced potential delisting due to non-compliance with Nasdaq rules. While this extension offers a reprieve, the company’s ability to fulfill these requirements remains uncertain.
Read more →NCELNLS Pharmaceutics Announces Publication of New Patent Application for Next-Gen Dual Non-Sulfonamide Orexin Receptor Agonists (DOXA) Zurich, Switzerland
NLS Pharmaceutics has announced the publication of a new patent application for its next-generation dual orexin receptor agonists, which target narcolepsy primarily and neurodegenerative conditions such as Parkinson's disease secondarily. This patent builds on NLS's existing license agreement with Aexon Labs and highlights advancements in treating central nervous system disorders. The newly presented compounds show promise with fewer issues related to receptor desensitization and efficacy loss. The announcement reflects NLS's ongoing commitment to develop therapies aimed at unmet medical needs.
Read more →NCELNLS Pharmaceutics Reports Positive Results from Study KO-874 on Mazindol's Neuroprotective Effects in Narcoleptic-like Rat Model ZÜRICH, SWITZERLAND / ACCESSWIRE /
NLS Pharmaceutics announced positive results from study KO-874, which evaluated the neuroprotective effects of mazindol in a narcoleptic-like rat model. Presented at the ASCP, the study showed that a 3 mg/kg dose of mazindol significantly restored nocturnal activity disrupted by orexin-B-saporin lesions. The findings underscore the potential of mazindol as a therapeutic option for narcolepsy and other sleep disorders, furthering NLS's commitment to advancing treatments in this space.
Read more →NCELNLS Pharmaceutics Announces Receipt of Additional Staff Delisting Determination from Nasdaq ZÜRICH, SWITZERLAND / ACCESSWIRE /
NLS Pharmaceutics has received an additional delisting determination from Nasdaq due to failing to meet the minimum stockholders' equity requirement. This follows previous notifications regarding non-compliance with bid price standards. The company has requested a hearing before the Nasdaq Hearings Panel to appeal this determination, where it plans to discuss measures to address these deficiencies. The hearing is scheduled for June 4, 2024.
Read more →NCELADDENDUM TO THE Loan Agreement " Agreement " of
NLS Pharmaceutics AG has agreed to extend the maturity date of its loan agreement until June 30, 2025. The other terms outlined in the original agreement will remain unchanged. This addendum signifies a mutual agreement between the borrower and lender, maintaining the existing contractual conditions otherwise.
Read more →NCELSECOND ADDENDUM TO THE Loan Agreement " Agreement " of
NLS Pharmaceutics AG has executed a second addendum to its loan agreement, extending the maturity date until June 30, 2025. This amendment keeps all other terms of the original agreement unchanged. The parties involved include NLS Pharmaceutics as borrower and lender Ronald Hafner. The agreement will be governed by Swiss law, with any disputes being addressed in Zurich's courts.
Read more →NCELNLS Pharmaceutics Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request Hearing ZÜRICH, SWITZERLAND / ACCESSWIRE /
NLS Pharmaceutics Ltd. has received a delisting determination letter from Nasdaq due to its failure to maintain a minimum bid price for its shares. The company plans to request a hearing to appeal this decision and present a compliance plan. Although NLS has strong clinical data supporting its lead candidate, Quilience, the outcome of the hearing and the ability to regain compliance with Nasdaq requirements remain uncertain.
Read more →NCELNLS Pharmaceutics Announces $1.75 Million Registered Direct Offering ZURICH, SWITZERLAND / ACCESSWIRE /
NLS Pharmaceutics Ltd. is set to conduct a registered direct offering of 7,000,000 common shares at a price of $0.25 per share, anticipating gross proceeds of $1.75 million. The closing of the offering is expected on or around March 22, 2024, subject to customary conditions. The company plans to utilize the net proceeds for working capital and general corporate expenses. H.C. Wainwright & Co. is managing the offering, which is conducted under a prior SEC registration statement.
Read more →NCELNLS Pharmaceutics Secures Exclusive Global License for Next-Generation Non-Sulfonamide Dual Orexin Agonist Platform The exclusive License Agreement grants NLS Pharmaceutics global rights to next-generation non-sulfonamid
NLS Pharmaceutics has secured an exclusive global license agreement with Aexon Labs for its next-generation Dual Orexin Receptor Agonist platform. This agreement grants NLS rights for development and commercialization of new oral agents targeting orexin receptors, showing promise for treating conditions like narcolepsy and Parkinson's disease. The compounds demonstrated positive preliminary results and aim to address significant healthcare needs. However, NLS must navigate potential market challenges and complete forthcoming clinical trials to validate these innovations.
Read more →NCELNasdaq Accepts NLS Pharmaceutics' Plan to Regain Listing Compliance Z rich, Switzerland
NLS Pharmaceutics Ltd. has received approval from the Nasdaq Listing Qualifications Department for its plan to regain compliance with the minimum stockholders' equity requirement. Originally notified on January 9, 2024, the company's compliance plan was submitted on February 23, and the approval grants NLS an additional 180 days, extending the deadline until July 8, 2024. This move is crucial for the company to maintain its listing on the Nasdaq Capital Market amid challenges in the biopharmaceutical industry.
Read more →NCELNLS Pharmaceutics Submits Plan to Regain Listing Compliance With Nasdaq Z rich, Switzerland
NLS Pharmaceutics Ltd. has announced the submission of a plan to regain compliance with Nasdaq Listing Rule 5550(b)(1), following a notification of non-compliance due to insufficient stockholders' equity. The company has until July 8, 2024, to meet the necessary requirements, potentially benefiting from a 180-day extension. NLS focuses on developing therapies for rare central nervous system disorders, aiming to meet unmet medical needs. The success of their plan will be crucial for maintaining their listing status on the Nasdaq exchange.
Read more →NCELNLS Pharmaceutics Announces Receipt of Notice of Deficiency with Nasdaq Continued Listing Requirements Z rich, Switzerland
NLS Pharmaceutics Ltd. has received a notice of deficiency from Nasdaq, indicating that it does not meet the minimum stockholders' equity requirement for continued listing. The company has until February 23, 2024, to submit a plan to regain compliance, which, if accepted, could extend the timeline by an additional 180 days. The management is actively looking into various options to ensure compliance and maintain its Nasdaq listing. Fortunately, the notice does not have an immediate impact on the company’s listing status.
Read more →NCELZ rich, Switzerland
NLS Pharmaceutics, a Swiss biopharmaceutical company, has shared an end-of-year letter from CEO Alex Zwyer to shareholders, outlining achievements and challenges faced in 2023. Highlighted progress includes positive Phase 2 trial results for its narcolepsy treatment, Mazindol ER, and the approval of a Phase 3 study protocol. The company has also entered into an option agreement for a new dual orexin receptor agonist platform intended for various sleep and neurodegenerative disorders. Despite challenging financing conditions, NLS aims to enhance shareholder value through strategic partnerships and innovations in treatment.
Read more →NCELNLS PHARMACEUTICS LTD. UNAUDITED INTERIM CONDENSED FINANCIAL STATEMENTS AS OF JUNE 30, 2023 AND DECEMBER 31, 2022 AND FOR THE SIX MONTH PERIODS ENDED JUNE 30, 2023 AND 2022 NLS PHARMACEUTICS LTD. UNAUDITED INTERIM CONDEN
NLS Pharmaceutics Ltd. has reported its unaudited interim condensed financial statements for the six months ending June 30, 2023. The company experienced a net loss of approximately $7.6 million during this period, with cash and cash equivalents decreasing to $1.6 million. As of the end of June 2023, the company has an accumulated deficit of around $65.8 million and anticipates continued operating losses for the foreseeable future. A significant portion of its financial resources has been allocated to research and development activities.
Read more →NCELTo the shareholders of NLS Pharmaceutics AG, Zurich, Switzerland Zurich, 1 December 2023 Invitation to the Extraordinary Shareholders' Meeting of NLS Pharmaceutics AG, Zurich, Switzerland Dear Shareholder, The board of d
NLS Pharmaceutics AG is convening an extraordinary shareholders' meeting on December 22, 2023. The board of directors proposes the election of Claudio Bassetti and Florence Allouche as new members. Shareholders can participate in the meeting either in person or through a proxy. Detailed voting instructions and registration requirements have been provided to ensure shareholders can exercise their rights effectively.
Read more →NCELNLS Pharmaceutics Announces Exclusive Option Agreement to Develop and Commercialize Next Generation Dual Orexin Agonist Platform of Aexon Labs, Inc. The option agreement grants NLS Pharmaceutics Ltd. the exclusive option
NLS Pharmaceutics has entered an exclusive option agreement with Aexon Labs to develop and commercialize a next-generation dual orexin receptor agonist platform. This agreement could enhance NLS's offerings in treating narcolepsy, idiopathic hypersomnia, and neurodegenerative conditions. Aexon Labs plans to begin clinical development in 2024, with promising pre-clinical results noted. NLS is responsible for all associated research and regulatory activities as part of this agreement.
Read more →NCELNLS Pharmaceutics Announces Election of Additional Board Members Professor Claudio L. A. Bassetti, MD, is the Chair, Neurology Department, Inselspital, Bern University Hospital and Dean, Medical Faculty, University of Be
NLS Pharmaceutics Ltd. has announced the election of Dr. Florence Allouche Aknin and Professor Claudio L. A. Bassetti to its board of directors, effective January 1, 2024, pending approval at the upcoming EGM. CEO Alex Zwyer expressed confidence that their expertise will significantly aid the company's mission in developing innovative therapies for central nervous system disorders. Both appointees bring extensive experience in their respective fields, Dr. Aknin in biopharmaceutical business and Professor Bassetti in neurology and sleep medicine.
Read more →NCELLoan Agreement " Agreement " of
NLS Pharmaceutics AG has entered into a loan agreement granting CHF 250,000 to the Borrower. The loan will bear an interest rate of 10% per annum and is intended for general financing purposes. The repayment is scheduled to occur by June 30, 2024, or upon a liquidity event with a strategic partner. The agreement emphasizes confidentiality regarding the terms and information shared between the parties involved.
Read more →NCELNLS Pharmaceutics Announces Receipt of Nasdaq Minimum Bid Price Notification Z rich, Switzerland
NLS Pharmaceutics Ltd. received a notification from Nasdaq regarding its non-compliance with the minimum bid price requirement of $1.00 per share. The company has a period of 180 days to meet this requirement and can continue trading on Nasdaq during this grace period. If the compliance is not regained by April 16, 2024, NLS may seek an additional 180-day extension, which could involve a reverse stock split. Failure to achieve compliance could lead to delisting from the exchange.
Read more →NCELLoan Agreement " Agreement " of 28 September 2023 between NLS Pharmaceutics AG The Circle 6 8058 Z rich Switzerland " Borrower " and Ronald Hafner Weinbergstrasse 72 8703 Erlenbach ZH Switzerland " Lender " (Borrower and
NLS Pharmaceutics AG has entered into a loan agreement with Ronald Hafner for CHF 500,000. The loan will be paid out within five business days and is to be used for the company's general financing and corporate purposes. The agreement also includes confidentiality clauses to protect the information exchanged between the parties. The loan carries an interest rate of 10% per annum and must be repaid by November 30, 2023.
Read more →NCELRe defining Central Nervous System Therapies NLS Pharmaceutics September 2023 2 Forward - Looking Statements This presentation contains express or implied forward - looking statements within the Private Securities Litiga
NLS Pharmaceutics is advancing its pipeline of CNS therapies, notably with Mazindol ER for narcolepsy, which has successfully completed Phase 2 trials. The company is preparing to start the Phase 3 AMAZE Program in the second half of 2023 while holding Orphan Drug Designation in the US and Europe for two indications. Their unique approach to drug development for rare CNS disorders is supported by strong patent protections and potential market opportunities projected to reach $4.5 billion by 2027. Despite these advancements, NLS faces risks including regulatory hurdles and competition in the pharmaceutical market.
Read more →NCELThank you for joining. The presentation will begin shortly. NLS Pharmaceutics Company Update
NLS Pharmaceutics provided an update on its company initiatives with a focus on advancing therapies for central nervous system disorders. The presentation emphasized their strategic priorities, which include initiating a Phase 3 program for the treatment of narcolepsy using Mazindol and progressing other compounds in their pipeline. The company's CEO highlighted the importance of their experienced team and the anticipated impacts on patient healthcare. NLS is preparing for potential commercialization and regulatory approvals based on encouraging clinical results.
Read more →NCELNLS Pharmaceutics Releases the Results from its Annual General Meeting Z rich, Switzerland
NLS Pharmaceutics held its Annual General Meeting in Zurich, Switzerland, where all proposals by the Board of Directors were overwhelmingly approved by shareholders. Notably, the election of Audrey Greenberg and Dr. Anthony Walsh to the Board brought U.S. representation. The company also received the highest voting approval rate in its history. The shareholders confirmed financial statements and compensation budgets for the upcoming year, reaffirming their support for the company's strategic direction.
Read more →NCELNLS Pharmaceutics Announces Positive Safety Data From In Vitro CYP450 and Transporter Mediated Drug-Drug Interaction Studies of Mazindol Very low risk for drug-drug interactions (DDI) with Mazindol ER based upon results
NLS Pharmaceutics announced positive results from in vitro drug-drug interaction studies for Mazindol, indicating it does not inhibit or induce drug metabolism. The results support the safety profile of Mazindol ER, suggesting it may offer advantages for narcolepsy patients on multiple concomitant medications. Following these findings, the company plans to initiate the AMAZE Phase 3 clinical program in July 2023, targeting narcolepsy type 1 patients. The studies aim to assess both safety and efficacy, with topline data expected in late 2024.
Read more →NCELTo the shareholders of NLS Pharmaceutics AG, Zurich, Switzerland Zurich, 8 June 2023 Invitation to the Ordinary Shareholders' Meeting of NLS Pharmaceutics AG, Zurich, Switzerland Dear Shareholder, The board of directors
NLS Pharmaceutics AG has invited its shareholders to the ordinary shareholders' meeting to be held in Zug, Switzerland. Key agenda items include the approval of the company's 2022 financial statements, re-election of board members, and the approval of compensation reports. Shareholders who wish to attend the meeting must register by June 25, 2023, and can also be represented by an independent proxy. The company aims to maintain transparency and shareholder engagement through these measures.
Read more →NCELNLS Pharmaceutics Appoints Keith Harrison Dewedoff as Interim Chief Financial Officer Z rich, Switzerland
NLS Pharmaceutics has appointed Keith Harrison Dewedoff as its Interim Chief Financial Officer. Dewedoff brings over 20 years of experience in the life sciences industry, which the company hopes will help in navigating the financial aspects of the upcoming Phase 3 program for its lead product, Quilience. The resignation of previous CFO Chad Hellmann, while he remains through the end of May for a smooth transition, adds a layer of complexity during this important phase for the company. The appointment comes as NLS aims to solidify its pipeline and meet the rising demands for therapies targeting complex CNS disorders.
Read more →NCELNLS Pharmaceutics Receives Green Light from the U.S. FDA to Proceed with Phase 3 Clinical Program (AMAZE) for Quilience (Mazindol ER) for the treatment of Narcolepsy Z rich, Switzerland
NLS Pharmaceutics has received authorization from the U.S. FDA to advance its Phase 3 clinical trials for Quilience (Mazindol ER), targeting narcolepsy treatment. The AMAZE program consists of two double-blind trials involving adult patients, which aim to measure the frequency of cataplexy episodes. This development follows the successful outcomes of their earlier Phase 2 studies, demonstrating the potential of Mazindol ER in addressing a significant gap in treatment options for narcolepsy patients. Recruitment for the trials is set to begin this summer, reflecting the company's commitment to improving patient outcomes in CNS disorders.
Read more →NCELNLS Pharmaceutics Announces Open Label Extension Study Six-Month Data for Quilience (Mazindol ER) in the Treatment of Narcolepsy Type 1 and Type 2 Patients treated with Mazindol ER in the randomized Phase 2 trial showed
NLS Pharmaceutics announced results from the Open Label Extension study for Quilience (Mazindol ER) in treating narcolepsy. After a four-week double-blind trial, 87% of participants opted for an additional six months on the drug, with reported reductions in excessive daytime sleepiness and cataplexy episodes. The study maintained a favorable safety profile with no serious adverse events, paving the way for a forthcoming Phase 3 program. NLS plans to present full data at the SLEEP 2023 conference this June.
Read more →NCELNLS Pharmaceutics Announces Completion of Open Label Extension Study with Quilience (Mazindol ER) for the Treatment of Narcolepsy Six-month Open Label Extension (OLE) study for patients that completed the POLARIS Phase 2
NLS Pharmaceutics has announced the completion of a six-month open-label extension study for its drug Quilience (Mazindol ER) in treating narcolepsy. The study included patients who successfully completed the prior POLARIS Phase 2 study, with 87% choosing to continue the treatment. The extension aims to evaluate long-term safety and efficacy, showcasing improved outcomes in managing Excessive Daytime Sleepiness (EDS) and cataplexy. Complete results are expected to be released in early 2023 and presented at a future scientific meeting.
Read more →NCELNLS Pharmaceutics Regains Compliance with Nasdaq Stockholders' Equity Requirement Z rich, Switzerland
NLS Pharmaceutics Ltd. has announced that it has regained compliance with Nasdaq's stockholders' equity requirement, as confirmed by the Hearings Panel. The company had received a notification regarding its initial non-compliance in April 2022, but after an appeal and subsequent actions, it successfully met the required equity standard. This development allows NLS to continue its listing on Nasdaq, marking a positive step for the company's prospects.
Read more →NCELNLS Pharmaceutics announces new in-vitro data reconfirming Quilience's (mazindol ER) unique dual mechanism of action involving significant Orexin-2 receptor activity The orexin deficit is believed to be the root cause of
NLS Pharmaceutics announced promising in vitro results for Quilience (mazindol ER), showing significant activity at the Orexin-2 receptor. The dual mechanism of action could provide a new approach to treating narcolepsy type 1, addressing the root of orexin deficiency rather than merely symptoms. The company plans to continue research and will commence a Phase 3 program in mid-2023. This development may position Quilience as a favorable option among existing narcolepsy treatments.
Read more →NCELNLS Pharmaceutics Announces an R&D Update Webcast to Review the Company's Growing Portfolio of Pre-clinical Compounds Management to Discuss Pipeline Goals and Development Strategies across four Preclinical and 2 Clinical
NLS Pharmaceutics has announced an upcoming R&D update webcast scheduled for January 31, 2023, highlighting its pre-clinical and clinical pipeline focused on rare CNS disorders. The company aims to present its strategic R&D progress and pipeline goals, showcasing its innovative therapies for conditions such as Idiopathic hypersomnia and Alzheimer’s-associated amnesia. Stakeholders can access the virtual event via the company's website. NLS's leadership plans to detail development strategies while acknowledging potential challenges in clinical trial success and product approvals.
Read more →NCELNLS Pharmaceutics Announces Technology Patent Grant Covering Mazindol for Treatment of Attention Deficit Hyperactivity Disorder and Rare Sleep Disorders in Hong Kong Hong Kong patent relates to Company's lead product can
NLS Pharmaceutics Ltd. announced the grant of a technology patent in Hong Kong for Mazindol ER, which is being developed for treating Attention Deficit Hyperactivity Disorder (ADHD) and rare sleep disorders. This patent is expected to remain in effect until at least 2037 and strengthens the company's position as it works toward launching its lead product candidate. Recent Phase 2 clinical trial results for Mazindol ER showed favorable outcomes, meeting primary endpoints and demonstrating strong safety profiles. NLS aims to leverage this patent alongside existing Orphan Drug Designations in the U.S. and Europe to expand its market presence.
Read more →NCELNLS Pharmaceutics CEO Issues Letter to Shareholders To our Shareholders and Friends, Just under two years ago, NLS Pharmaceutics sought your investment and support to advance our pipeline in rare sleep disorders and othe
NLS Pharmaceutics CEO Issues Letter to Shareholders To our Shareholders and Friends, Just under two years ago, NLS Pharmaceutics sought your investment and support to advance our pipeline in rare sleep disorders and other rare and debilitating Central Nervous System disorders.
Read more →NCELNLS Pharmaceutics Announces Israeli Patent Grant Covering Mazindol for Treatment of Attention Deficit Hyperactivity Disorder and Other Sleep Disorders Through 2037 Israeli patent relates to Mazindol use in attention defi
NLS Pharmaceutics Announces Israeli Patent Grant Covering Mazindol for Treatment of Attention Deficit Hyperactivity Disorder and Other Sleep Disorders Through 2037 Z rich, Switzerland, December 20, 2022 - NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) ("NLS" or the "Company"), a
Read more →NCELNLS Pharmaceutics Announces Closing of Initial Tranche of US$10.0 Million Purchase Agreement with BVF Partners L.P. Financing provided exclusively by leading healthcare fund BVF Partners L.P. Cash runway potentially secu
NLS Pharmaceutics Announces Closing of Initial Tranche of US$10.0 Million Purchase Agreement with BVF Partners L.P. Switzerland, December 14, 2022 - NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company, focused
Read more →NCELNEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAS BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM
NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAS BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED
Read more →NCELNLS Pharmaceutics Announces Notice of Allowance for U.S. Patent Covering Mazindol for Opioid Dependence and Substance Use Disorder More than 100,000 deaths in the U.S. alone each year due to overdose Global Opioid Use Di
Pharmaceutics Announces Notice of Allowance for U.S. Patent Covering Mazindol for Opioid Dependence and Substance Use Disorder Z rich, Switzerland, December 1, 2022 - NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutica
Read more →NCELNLS Pharmaceutics Announces Launch of Paid for Named Patient Program with Mazindol ER for Idiopathic Hypersomnia, a Serious Sleep Disorder with No Approved Treatment Options in Europe Zurich, Switzerland
NLS Pharmaceutics Announces Launch of Paid for Named Patient Program with Mazindol ER for Idiopathic Hypersomnia, a Serious Sleep Disorder with No Approved Treatment Options in Zurich, Switzerland, November 23, 2022 - NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) ("NLS" or the
Read more →NCELNLS Pharmaceutics Successfully Appeals Nasdaq Delisting Notice Switzerland/Zurich
Successfully Appeals Nasdaq Delisting Notice November 14, 2022 - NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and c
Read more →NCELNLS Pharmaceutics Provides Open Label Extension Study Update for Quilience (Mazindol ER) in the Treatment of Narcolepsy Patients treated with Quilience in the randomized Phase 2 trial continue to improve after rolling ov
Pharmaceutics Provides Open Label Extension Study Update for Quilience (Mazindol ER) in the Treatment of Narcolepsy November 7, 2022 - NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discover
Read more →NCELU.S. FDA Grants Orphan Drug Designation (ODD) for Quilience Ò (Mazindol ER) for the Treatment of Idiopathic Hypersomnia (IH) ODD for IH in the U.S. follows July 2022 grant of ODD for treatment of IH in Europe Curr
FDA Grants Orphan Drug Designation (ODD) for Quilience (Mazindol ER) for the Treatment of Idiopathic Hypersomnia (IH) Switzerland/Zurich, November 2, 2022 - NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company
Read more →NCELNLS PHARMACEUTICS LTD. UNAUDITED INTERIM CONDENSED FINANCIAL STATEMENTS AS OF AND FOR THE SIX MONTHS ENDED JUNE 30, 2022 AND 2021 NLS PHARMACEUTICS LTD. UNAUDITED INTERIM CONDENSED FINANCIAL STATEMENTS Page Unaudited Int
NLS PHARMACEUTICS LTD. UNAUDITED INTERIM CONDENSED FINANCIAL STATEMENTS AS OF AND FOR THE SIX MONTHS ENDED JUNE 30, 2022 NLS PHARMACEUTICS LTD. UNAUDITED INTERIM CONDENSED FINANCIAL STATEMENTS Page Unaudited Interim Condensed Balance Sheets as of June 30, 2022 and December
Read more →NCELTo the shareholders of NLS Pharmaceutics AG, Zurich, Switzerland Zurich
To the shareholders of NLS Pharmaceutics AG, Zurich, Switzerland Zurich, October 5, 2022 Extraordinary Shareholders' Meeting of NLS Pharmaceutics AG, Zurich, The board of directors of NLS Pharmaceutics AG (the "Board of Directors"), with registered office at the Circle 6, 80
Read more →NCELNLS Pharmaceutics Announces Positive Top-Line Results from its Phase 2a Clinical Trial of Once-Daily Quilience (Mazindol ER) for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Patients with Narcolepsy Sta
NLS Pharmaceutics Announces Positive Top-Line Results from its Phase 2a Clinical Trial of Once-Daily Quilience (Mazindol ER) for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Patients with Narcolepsy September 27, 2022 - NLS Pharmaceutics Ltd. (Nasdaq: NLSP, N
Read more →NCELNLS Pharmaceutics Appoints Dr. George Apostol as Chief Medical Officer and Global Head of Research & Development Company also announces expected departure of Sylvia Panigone, Ph.D. Switzerland/Zurich
NLS Pharmaceutics Appoints Dr. George Apostol as Chief Medical Officer and Global Head of Research & Development Company also announces expected departure of Sylvia Panigone, Ph.D. Switzerland/Zurich, September 8, 2022 - NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) ("NLS" o
Read more →NCELShort-term Note ("Agreement") dated as of
as of August 19, 2022 entered into by and among NLS Pharmaceutics AG The Circle 6 8058 Z rich Switzerland the "Borrower" and the "Company") Lenders and the Borrower each a "Party" and collectively the "Parties") 1. Definitions 2 2. Loan 2 3. Lenders' Rights and Obligatio
Read more →NCELNLS Pharmaceutics Announces Decision by Japanese Patent Office to Grant Patent in Japan for Mazindol Extended-Release Key patents now granted in major markets including the U.S., Europe, Japan, Canada & South Korea Paten
NLS Pharmaceutics Announces Decision by Japanese Patent Office to Grant Patent in Japan for Mazindol Extended-Release July 28, 2022 - NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discover
Read more →NCELNLS Pharmaceutics Announces Positive Opinion from European Regulators to Grant Orphan Drug Designation for Mazindol ER in Idiopathic Hypersomnia Switzerland/Zurich
NLS Pharmaceutics Announces Positive Opinion from European Regulators to Grant Orphan Drug Designation for Mazindol ER in Idiopathic Hypersomnia Switzerland/Zurich, July 21, 2022 - NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage bi
Read more →NCELNLS Pharmaceutics Announces Receipt of Nasdaq Minimum Bid Price Notification Switzerland/Zurich
Announces Receipt of Nasdaq Minimum Bid Price Notification Switzerland/Zurich, June 10, 2022 - NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapi
Read more →NCELNLS Pharmaceutics Appoints Chad C. Hellmann as Chief Financial Officer Switzerland/Zurich
NLS Pharmaceutics Appoints Chad C. Hellmann as Chief Financial Officer Switzerland/Zurich, June 6, 2022 - NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innova
Read more →NCELNLS Pharmaceutics Announces Over Enrollment in its Phase 2a Clinical Trial Evaluating Quilience for the Treatment of Narcolepsy 60-patient enrollment target met plus 12% over-enrollment; top-line Phase 2a results expecte
Pharmaceutics Announces Over Enrollment in its Phase 2a Clinical Trial Evaluating Quilience for the Treatment of June 2, 2022 - NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and d
Read more →NCELTo the shareholders of NLS Pharmaceutics AG, Zurich, Switzerland Zurich, 9 May 2022 Invitation to the Ordinary Shareholders' Meeting of NLS Pharmaceutics AG, Zurich, Switzerland Dear Shareholder, The board of directors o
To the shareholders of NLS Pharmaceutics AG, Zurich, Switzerland Ordinary Shareholders' Meeting of NLS Pharmaceutics AG, Zurich, Switzerland The board of directors of NLS Pharmaceutics AG (the "Board of Directors"), with registered office at the Circle 6, 8058 Zurich, Switzer
Read more →NCELNLS Pharmaceutics Achieves 90% Enrollment Milestone in Quilience Phase 2a Clinical Trial for Patients with Narcolepsy Since the interim results were released in March, patient enrollment has nearly doubled Of the 60 pati
NLS Pharmaceutics Achieves 90% Enrollment Milestone in Quilience Phase 2a Clinical Trial for Patients with Narcolepsy Switzerland/Zurich, May 4, 2022 - NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focus
Read more →NCELNLS Pharmaceutics Ltd. Announces Closing of US$4.4 Million Registered Direct Offering ZURICH, SWITZERLAND / ACCESSWIRE /
NLS Pharmaceutics Ltd. Announces Closing of US$4.4 Million Registered Direct Offering ZURICH, SWITZERLAND / ACCESSWIRE / April 26, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on t
Read more →NCELNLS Pharmaceutics Ltd. Announces US$4.4 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules ZURICH, SWITZERLAND / ACCESSWIRE /
NLS Pharmaceutics Ltd. Announces US$4.4 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules ZURICH, SWITZERLAND / ACCESSWIRE / April 13, 2022 / NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutica
Read more →NCELInvestor Presentation | April 2022 Alexander Zwyer, CEO & Co - Founder defining Central Nervous System Therapies Forward - Looking Statements This presentation contains express or implied forward - looking statements wit
Investor Presentation | April 2022 Alexander Zwyer, CEO & Co - Founder defining Central Nervous System Therapies Forward - Looking Statements This presentation contains express or implied forward - looking statements within the Private Securities Litigation Reform Act of 1995 an
Read more →NCELNLS Pharmaceutics Announces Receipt of Notice of Deficiency with Nasdaq Continued Listing Requirements Switzerland/Zurich
NLS Pharmaceutics Announces Receipt of Notice of Deficiency with Nasdaq Continued Listing Requirements Switzerland/Zurich, April 1, 2022 - NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the di
Read more →NCELNLS Pharmaceutics Retains LifeSci Partners As Financial Advisor To Evaluate Strategic Partnering Initiatives Switzerland/Zurich
NLS Pharmaceutics Retains LifeSci Partners As Financial Advisor To Evaluate Strategic Partnering Initiatives Switzerland/Zurich, March 31, 2022 - NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on
Read more →NCELNLS Pharmaceutics Announces Early Access Program (EAP) Allowing Patients with Idiopathic Hypersomnia to Receive Treatment with Mazindol ER Named Patient Program (NPP) enables physicians to prescribe the Company's novel M
NLS Pharmaceutics Announces Early Access Program (EAP) Allowing Patients with Idiopathic Hypersomnia to Receive Treatment with Mazindol ER Switzerland/Zurich, March 28, 2022 - NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biophar
Read more →NCELNLS Pharmaceutics Announces Positive Interim Top-Line Data for Quilience (Mazindol ER) in Patients with Narcolepsy Clinically meaningful results with Mazindol ER exhibiting a 39% reduction in ESS from baseline (-4.3 poin
NLS Pharmaceutics Announces Positive Interim Top-Line Data for Quilience (Mazindol ER) in Patients with Narcolepsy Switzerland/Zurich, March 16, 2022 - NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focu
Read more →NCELNLS Pharmaceutics to Present Interim Top-Line Data for Quilience (Mazindol ER) in Patients with Narcolepsy at the World Sleep Congress in March 2022 Phase 2a trial meets enrollment target for interim analysis and is now
NLS Pharmaceutics to Present Interim Top-Line Data for Quilience (Mazindol ER) in Patients with Narcolepsy at the World Sleep Congress in March 2022 Switzerland/Zurich, February 7, 2022 - NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-s
Read more →NCELNLS Pharmaceutics Announces Patent Issuance in the United States for its Mazindol Extended-Release Formulation Key patent now granted in major markets including the U.S., Europe, Canada & South Korea Patent claims cover
Pharmaceutics Announces Patent Issuance in the United States for its Mazindol Extended-Release Formulation patent now granted in major markets including the U.S., Europe, Canada & South Korea claims cover use of the Company's lead product candidate, Quilience (mazindol ER) in b
Read more →NCELSTANDBY EQUITY DISTRIBUTION AMENDMENT AGREEMENT This amendment agreement dated as of
STANDBY EQUITY DISTRIBUTION This amendment agreement dated as of December 14, 2021 (the "Amendment Agreement") is between YA II PN, LTD., a Cayman Islands exempt limited partnership (the "Investor"), and NLS PHARMACEUTICS LTD., a company incorporated under the laws of Switzerl
Read more →NCELShare Option Plan Regulation 2021 of NLS Pharmaceutics Ltd. ( Company ) Table of Content 1. INTRODUCTION 1 2. THE PLAN 1 2.1 GENERAL TERMS AND DEFINITIONS 1 2.2. ADMINISTRATION OF THE PLAN 5 2.3. GRANT OF OPTIONS 5 2.4.
Option Plan Regulation 2021 Table of Content 1. INTRODUCTION 1 2. THE PLAN 1 2.1 GENERAL TERMS AND DEFINITIONS 1 2.2. ADMINISTRATION OF THE PLAN 5 2.3. GRANT OF OPTIONS 5 2.4. LIMITATIONS ON TRANSFER 7 2.5. CORPORATE TRANSACTION 8 2.6. FORFEITURE OF RIGHTS 9 2.7. GENERAL
Read more →NCELNLS Pharmaceutics Announces Preclinical Results Confirming the Potential Benefit and Safety Profile of NLS-4 for Circadian Rhythm Dysregulation and Chronic Fatigue Syndrome in Long-Covid Model Switzerland/Stans
Pharmaceutics Announces Preclinical Results Confirming the Potential Benefit and Safety Profile of NLS-4 for Circadian Rhythm Dysregulation and Chronic Fatigue Syndrome in Long-Covid Model November 30, 2021 - NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) ("NLS" or the "Company")
Read more →NCELTo the shareholders of NLS Pharmaceutics AG, Stans, Switzerland Stans, 9 November 2021 Invitation to the Extraordinary Shareholders' Meeting of NLS Pharmaceutics AG, Stans Dear Shareholder, The board of directors of NLS
To the shareholders of NLS Pharmaceutics AG, Stans, Switzerland Stans, 9 November 2021 Extraordinary Shareholders' Meeting of NLS Pharmaceutics The board of directors of NLS Pharmaceutics AG (the "Board of Directors"), with registered office at Alter Postplatz 2, 6370 Stans,
Read more →NCELNLS Pharmaceutics CEO Issues Letter to Shareholders Switzerland/Stans
NLS Pharmaceutics CEO Issues Letter to Shareholders Switzerland/Stans, November 1, 2021 - NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies fo
Read more →NCELNLS Pharmaceutics Announces Preclinical Data Demonstrating the Potential of NLS-4 (Lauflumide) to Treat Chronic Fatigue Associated With Long-COVID Switzerland/Stans
NLS Pharmaceutics Announces Preclinical Data Demonstrating the Potential of NLS-4 (Lauflumide) to Treat Chronic Fatigue Associated With Long-COVID Switzerland/Stans, October 14, 2021 - NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stag
Read more →NCELNLS PHARMACEUTICS LTD. UNAUDITED INTERIM CONDENSED FINANCIAL STATEMENTS AS OF AND FOR THE SIX MONTHS ENDED JUNE 30, 2021 AND 2020 NLS PHARMACEUTICS LTD. UNAUDITED INTERIM CONDENSED FINANCIAL STATEMENTS Page Unaudited Int
NLS PHARMACEUTICS LTD. UNAUDITED INTERIM CONDENSED FINANCIAL STATEMENTS AS OF AND FOR THE SIX MONTHS ENDED JUNE 30, 2021 NLS PHARMACEUTICS LTD. UNAUDITED INTERIM CONDENSED FINANCIAL STATEMENTS Page Unaudited Interim Condensed Balance Sheets as of June 30, 2021 and December
Read more →NCELSTANDBY EQUITY DISTRIBUTION AGREEMENT THIS STANDBY EQUITY DISTRIBUTION AGREEMENT (this " Agreement ") dated as of
STANDBY EQUITY DISTRIBUTION AGREEMENT THIS STANDBY EQUITY DISTRIBUTION AGREEMENT (this "Agreement") dated as of September 27, 2021 is made by and between YA II PN, LTD., a Cayman Islands exempt limited partnership (the "Investor"), and NLS PHARMACEUTICS LTD., a company incorp
Read more →NCELNLS Initiates Phase 2 Trial for Quilience in Narcolepsy and Announces First Patient Enrolled Switzerland/Stans
NLS Initiates Phase 2 Trial for Quilience in Narcolepsy and Announces First Patient Enrolled September 14, 2021 - NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused on the discovery and development of in
Read more →NCELNLS Pharmaceutics Announces Notice of Allowance for U.S. Patent Application Covering its Proprietary Mazindol Formulation Switzerland/Stans
Pharmaceutics Announces Notice of Allowance for U.S. Patent Application Covering its Proprietary Mazindol Formulation August 19, 2021 - NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused on the discovery
Read more →NCELNLS Pharmaceutics Announces the Appointment of Eric Konofal, M.D., Ph.D. as Chief Scientific Officer Switzerland/Stans
Pharmaceutics Announces the Appointment of Eric Konofal, M.D., Ph.D. as Chief Scientific Officer July 19, 2021 - NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused on the discovery and development of inno
Read more →NCELNLS Pharmaceutics Announces FDA Acceptance of IND Application to Initiate Clinical Trials with Quilience (mazindol ER) to Treat Narcolepsy Planned Phase 2a clinical trial anticipated to commence in August 2021 Switzerlan
NLS Pharmaceutics Announces FDA Acceptance of IND Application to Initiate Clinical Trials with Quilience (mazindol ER) to Treat Narcolepsy Planned Phase 2a clinical trial anticipated to commence Switzerland/Stans, July 15, 2021 - NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) (
Read more →NCELInvestor Presentation | July 2021 Alexander Zwyer, CEO & Co - Founder defining Central Nervous System Therapies Forward - Looking Statements This presentation contains express or implied forward - looking statements with
Investor Presentation | July 2021 Alexander Zwyer, CEO & Co - Founder defining Central Nervous System Therapies Forward - Looking Statements This presentation contains express or implied forward - looking statements within the Private Securities Litigation Reform Act of 1995 and
Read more →NCELTo the shareholders of NLS Pharmaceutics AG, Stans, Switzerland Stans, 21 May 2021 Invitation to the Ordinary Shareholders' Meeting of NLS Pharmaceutics AG, Stans Dear Shareholder, The board of directors of NLS Pharmaceu
To the shareholders of NLS Pharmaceutics AG, Stans, Switzerland Ordinary Shareholders' Meeting of NLS Pharmaceutics AG, Stans The board of directors of NLS Pharmaceutics AG (the "Board of Directors"), with registered office at Alter Postplatz 2, 6370 Stans, Switzerland (the "
Read more →NCELNLS Pharmaceutics Appoints Silvia Panigone, Ph.D. As Chief Operating Officer Switzerland/Stans
NLS Pharmaceutics Appoints Silvia Panigone, Ph.D. As Chief Operating Officer April 5, 2021 - NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused on the discovery and development of innovative therapies fo
Read more →NCELCon f i d e n t i a l Redefining Central Nervous System Therapies Investor Presentation March 2021 Alex Zwyer, CEO Redefining Central Nervous System Therapies Investor Presentation April 2021 Alexander Zwyer, CEO Forward
Con f i d e n t i a l Redefining Central Nervous System Therapies Investor Presentation March 2021 Alex Zwyer, CEO Redefining Central Nervous System Therapies Investor Presentation April 2021 Alexander Zwyer, CEO Forward Looking Statements 2 This presentation contains express or
Read more →NCELNLS Pharmaceutics Obtains License to Full Regulatory Data Package and Proprietary Know-How for Sanorex (Mazindol) Agreement provides exclusive rights to all available data included in the original new drug application ("
NLS Pharmaceutics Obtains License to Full Regulatory Data Package and Proprietary Know-How for Sanorex (Mazindol) Agreement provides exclusive rights to all available data included in the original new drug application ("NDA") for mazindol in the U.S. Switzerland/Stans, Marc
Read more →NCELNLS Pharmaceutics Ltd. Announces Closing of $20.0 Million Initial Public Offering
NLS Pharmaceutics Ltd. Announces Closing of $20.0 Million Initial Public Offering STANS, Switzerland - February 2, 2021 - NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused on the discovery and developm
Read more →NCELNLS Pharmaceutics Ltd. Announces Pricing of $20.0 Million Initial Public Offering
Ltd. Announces Pricing of $20.0 Million Initial Public Offering Switzerland - January 28, 2021 - NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused on the discovery and development of innovative therapies
Read more →Competitive Position
How NCEL ranks across every disease it competes inCompetitive Position is a premium feature
See how NCEL ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial